References

Obesity: global epidemiology and pathogenesis

10.1038/s41574-019-0176-8 · 2019 · External reference

Mechanisms, pathophysiology, and management of obesity

10.1056/nejmra1514009 · 2017 · External reference

2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery

10.1016/j.soard.2022.08.013 · 2022 · External reference

Once-weekly semaglutide in adults with overweight or obesity

10.1056/nejmoa2032183 · 2021 · External reference

Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial

10.1001/jama.2021.3224 · 2021 · External reference

Pharmacology, physiology, and mechanisms of incretin hormone action

10.1016/j.cmet.2013.04.008 · 2013 · External reference

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update

10.1111/dom.14496 · 2021 · External reference

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

10.2337/db10-0474 · 2011 · External reference

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

10.1111/dom.14280 · 2021 · External reference

Glucose-dependent insulinotropic polypeptide (GIP)

10.1016/j.molmet.2025.102118 · 2025 · External reference

Tirzepatide once weekly for the treatment of obesity

10.1056/nejmoa2206038 · 2022 · External reference

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

10.1056/nejmoa2107519 · 2021 · External reference

Investigating GIPR (ant)agonism: a structural analysis of GIP and its receptor

10.1016/j.str.2021.04.001 · 2021 · External reference

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

10.1016/j.molmet.2018.12.001 · 2019 · External reference

Stimulating intestinal GIP release reduces food intake and body weight in mice

10.1016/j.molmet.2024.101945 · 2024 · External reference

Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice

10.1038/s42255-023-00931-7 · 2023 · External reference

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

10.1016/j.molmet.2025.102298 · 2026 · External reference

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

10.1038/nm727 · 2002 · External reference

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

10.1172/jci25483 · 2007 · External reference

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

10.1126/scitranslmed.aat3392 · 2018 · External reference

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists

10.1210/endrev/bnz002 · 2020 · External reference

Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies

10.2337/db25-0393 · 2025 · External reference

GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale

10.2337/dbi24-0027 · 2025 · External reference

The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs

10.3390/jcm14113812 · 2025 · External reference

GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro

10.1016/s0167-0115(97)00009-8 · 1997 · External reference

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

10.2337/diabetes.51.3.652 · 2002 · External reference

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity

10.2337/diabetes.48.4.758 · 1999 · External reference

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

10.1677/joe.0.1650639 · 2000 · External reference

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

10.1007/s00125-002-1028-x · 2003 · External reference

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes

10.2337/diabetes.54.8.2436 · 2005 · External reference

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets

10.1007/s00125-007-0710-4 · 2007 · External reference

A gastric inhibitory polypeptide. II. The complete amino acid sequence

10.1139/o71-122 · 1971 · External reference

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

10.1210/jcem-37-5-826 · 1973 · External reference

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

10.2337/db11-0979 · 2011 · External reference

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

10.2337/diab.44.10.1202 · 1995 · External reference

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

10.1210/endo.133.6.8243312 · 1993 · External reference

Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes

10.1038/s42255-024-01061-4 · 2024 · External reference

The Role of Incretins on Insulin Function and Glucose Homeostasis

10.1210/endocr/bqab065 · 2021 · External reference

The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone

10.1016/j.peptides.2020.170276 · 2020 · External reference

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

10.1126/sciadv.abf1948 · 2021 · External reference

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

10.1172/jci116186 · 1993 · External reference

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

10.1007/s00125-008-1195-5 · 2009 · External reference

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response

10.1152/ajpendo.00347.2016 · 2017 · External reference

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

10.2337/db17-0480 · 2017 · External reference

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

10.2337/db18-1123 · 2019 · External reference

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

10.1016/j.cmet.2019.07.013 · 2019 · External reference

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

10.1016/j.cmet.2021.01.015 · 2021 · External reference

Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality

10.1016/j.bone.2013.07.003 · 2013 · External reference

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

10.1172/jci146353 · 2021 · External reference

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor

10.1016/j.cmet.2024.05.010 · 2024 · External reference

The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice

10.1016/j.cmet.2024.11.003 · 2025 · External reference

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans

10.1126/scitranslmed.3007218 · 2013 · External reference

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

10.1016/j.molmet.2018.09.009 · 2018 · External reference

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

10.1016/s0140-6736(18)32260-8 · 2018 · External reference

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

10.1172/jci.insight.140532 · 2020 · External reference

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

10.1038/s41591-023-02597-w · 2023 · External reference

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

10.1001/jama.2023.24945 · 2024 · External reference

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models

10.2337/db21-0459 · 2021 · External reference

GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior

10.2337/db21-0848 · 2022 · External reference

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

10.1056/nejmoa2301972 · 2023 · External reference

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

10.1038/ng.686 · 2010 · External reference

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge

10.1038/ng.521 · 2010 · External reference

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture

10.1038/ng.2606 · 2013 · External reference

Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH(2) on GIP actions in humans

10.1111/dom.14186 · 2021 · External reference

Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice

10.1002/osp4.164 · 2018 · External reference

Pharmacological antagonism of the incretin system protects against diet-induced obesity

10.1016/j.molmet.2019.11.018 · 2020 · External reference

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

10.1371/journal.pone.0249239 · 2021 · External reference

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys

2021 · External reference

AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys

10.1016/j.molmet.2024.102006 · 2024 · External reference

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

10.1038/s42255-023-00966-w · 2024 · External reference

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial

10.1056/nejmoa2504214 · 2025 · External reference

GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice

10.1038/s42255-025-01294-x · 2025 · External reference

GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice

10.1038/s42255-025-01295-w · 2025 · External reference

Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism

10.1038/s42255-026-01575-z · 2026 · External reference

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss

10.1016/j.molmet.2024.102074 · 2025 · External reference

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

10.1038/s41467-020-18751-8 · 2020 · External reference

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation

10.1016/j.molmet.2025.102094 · 2025 · External reference

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice

10.1111/dom.70300 · 2026 · External reference

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance

10.1152/ajpendo.00073.2012 · 2012 · External reference

The Importance of Endogenously Secreted GLP-1 and GIP for Postprandial Glucose Tolerance and β-Cell Function After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Surgery

10.2337/db22-0568 · 2023 · External reference

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

10.1038/ijo.2016.121 · 2016 · External reference

Pharmacologic management of weight regain following bariatric surgery

2022 · External reference

Mechanisms of weight recurrence after bariatric surgery

10.1186/s12986-026-01115-2 · 2026 · External reference

Weight Regain Following Sleeve Gastrectomy-a Systematic Review

10.1007/s11695-016-2152-x · 2016 · External reference

Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study

10.1007/s11695-024-07137-0 · 2024 · External reference

GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis

10.1007/s00423-025-03831-4 · 2025 · External reference

Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis

10.1007/s11695-025-08414-2 · 2025 · External reference

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis

10.1007/s11695-025-07733-8 · 2025 · External reference

Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study

10.1007/s00464-025-11942-8 · 2025 · External reference

Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence

10.1002/oby.23736 · 2023 · External reference

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study

10.1007/s11695-023-06484-8 · 2023 · External reference

The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis

10.1007/s11695-022-06211-9 · 2022 · External reference

10.1002/oby.22719

10.1002/oby.22719 · 2020 · External reference